Psychiatry UK: Company Profile
Background
Overview
Psychiatry UK is the UK's leading provider of digital psychiatry services, delivering expert, patient-centred mental health care to children, teenagers, and adults. Established in 2012, the company operates in partnership with the NHS and offers private services, utilizing secure digital technology to eliminate traditional barriers to accessing high-quality psychiatric support.
Mission and Vision
The mission of Psychiatry UK is to improve access to mental health care in the UK and to be part of the solution to the growing mental health crisis. The company envisions providing convenient, accessible, adaptable, confidential, economic, and tailored services to meet a wide range of mental health needs.
Primary Area of Focus
Psychiatry UK specializes in the assessment, diagnosis, and treatment of various mental health conditions, including:
- ADHD in adults and children
- Autism Spectrum Disorder (ASD) in adults and children
- Dementia and memory loss
- Addiction
- Stress and anxiety
- Mood disorders and depression
The company is regulated by the Care Quality Commission (CQC) and operates under the NHS Right to Choose (RTC) scheme for adult ADHD and ASD services.
Industry Significance
As a leading provider of digital psychiatry services in the UK, Psychiatry UK plays a crucial role in addressing the increasing demand for accessible and timely mental health care. By leveraging digital technology, the company enhances the reach and efficiency of psychiatric services, contributing significantly to the mental health sector.
Key Strategic Focus
Core Objectives
- Accessibility: Provide convenient and timely access to mental health services through digital platforms.
- Quality Care: Deliver high-quality, patient-centred psychiatric assessments and treatments.
- Innovation: Integrate advanced technologies, including AI-enabled tools, to support clinical decision-making and improve patient outcomes.
Specific Areas of Specialization
- ADHD and ASD Assessments: Offer comprehensive evaluations and management plans for Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder across all age groups.
- Mental Health Conditions: Address a broad spectrum of mental health issues, such as anxiety, depression, mood disorders, and addiction.
Key Technologies Utilized
- Telepsychiatry Platforms: Utilize secure digital platforms to conduct remote psychiatric assessments and consultations.
- AI-Enabled Tools: Implement artificial intelligence to assist in clinical decision-making, quality assurance, and patient safety.
Primary Markets or Conditions Targeted
- NHS Collaborations: Provide services under the NHS Right to Choose scheme, focusing on adult ADHD and ASD assessments.
- Private Sector: Offer private psychiatric services to individuals seeking timely and accessible mental health care.
Financials and Funding
Specific details regarding Psychiatry UK's funding history, total funds raised, recent funding rounds, and notable investors are not publicly disclosed. The company continues to invest in technological advancements and service expansion to meet the growing demand for mental health services.
Pipeline Development
Psychiatry UK is continually enhancing its service offerings, focusing on:
- Service Expansion: Increasing the capacity to handle a higher volume of assessments and treatments.
- Technological Integration: Integrating advanced technologies to improve service delivery and patient outcomes.
- Clinical Research: Engaging in research to develop evidence-based practices and treatments in digital psychiatry.
Technological Platform and Innovation
Proprietary Technologies
- Telepsychiatry Infrastructure: A secure digital platform facilitating remote psychiatric consultations and assessments.
- AI-Driven Decision Support: Tools that assist clinicians in making informed decisions, enhancing diagnostic accuracy and treatment efficacy.
Significant Scientific Methods
- Digital Assessments: Utilization of online questionnaires and tools to conduct comprehensive psychiatric evaluations.
- Data Analytics: Employing data analysis techniques to monitor patient progress and outcomes, informing continuous improvement.
Leadership Team
Psychiatry UK's leadership team comprises experienced professionals dedicated to advancing the company's mission:
- Nell Montgomery: Chief Executive Officer
An executive coach, psychotherapist, and former investment banker, Nell has been with Psychiatry UK since September 2023 and became CEO in 2024.
- Dr. Jo Farrow: Chief Medical Officer
An experienced clinician with expertise in managing services at the director level, Dr. Farrow has a thorough understanding of good governance in organizations, including creating, developing, and leading clinical and management teams.
- Dr. Andy Montgomery: Emeritus Medical Director and Co-Founder
A qualified doctor and psychiatrist with a doctorate in neuroscience, Dr. Montgomery's special interests include the pharmacological management of mood and anxiety disorders, ADHD, and schizophrenia.
- Mark Jackson: Chair of the Board
Founder of Redde Ltd (1992) and Assura Group (2003), Mark joined Psychiatry UK as Chair of the Board in November 2024. He also holds roles as Non-Executive Chairman of Frontier Medical Group, Limbs & Things, and BN Care.
- Ben Iversen: Chief Financial Officer, Board Member
With over thirty years of experience in corporate finance, Ben has held senior roles at several private UK-based companies and has been a key advisor to Psychiatry UK since June 2023.
- Andrea Dowling: Chief People Officer, Board Member
A senior HR leader with extensive experience in global financial services, Andrea operates as Chief People Officer, delivering people strategies that support Psychiatry UK’s continued growth.
- Anna Matty: Chief Commercial & Operating Officer
Formerly COO and Executive Board Member at AXA Health, Anna has held various senior leadership roles at Experian, BT Wholesale, and BT before becoming Chief Commercial & Operating Officer at Psychiatry UK, tasked with leading the company's transformation.
- Dr. Lesa S. Wright: Chief Digital Officer & Consultant Psychiatrist
Dr. Wright focuses on AI regulation and safety, representing the Royal College of Psychiatrists on MHRA advisory groups. As a clinical safety officer, she prioritizes patient safety in AI healthcare development, innovating in mental health with a safety-first philosophy.
- Mark Contreras: Chief Technology Officer
With extensive senior technology leadership experience from retail banking, Mark is focused on transforming the technology and teams to ensure they continue to support the company’s future growth ambitions.
- Natasha Sloman: Director of Quality and Safety
Natasha's passion for advocating for patients empowers those with lived experience to help shape best-in-class governance in mental health. Her extensive on-the-ground practice puts her at the heart of Psychiatry UK’s undertaking to deliver safe, efficient, high-quality care for patients.
- Bev Sydney: Head of Corporate Governance
With nearly 30 years of experience in governance and change delivery roles across the private sector, health, and local government, Bev leads on the development and oversight of Psychiatry UK’s corporate governance arrangements.
Competitor Profile
Market Insights and Dynamics
The mental health care sector in the UK is experiencing significant growth, driven by increasing awareness and demand for services. Digital health solutions are becoming increasingly important, offering accessible and timely care. Psychiatry UK, as a leading digital psychiatry provider, is well-positioned to capitalize on these trends.
Competitor Analysis
- Cygnet Health Care: An independent provider of health and social care services for young people and adults with mental health needs, acquired brain injuries, eating disorders, autism, and learning disabilities within the UK.
- Priory Group: A provider of mental health care and addiction rehabilitation facilities in the UK.
